Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sivan Weiss"'
Publikováno v:
ERJ Open Research, Vol 3, Iss 3 (2017)
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This s
Externí odkaz:
https://doaj.org/article/dbc948311d364533ba22682b65ae5ef6
Autor:
Pippa S. Loupe, David J. Greenblatt, Arik A. Zur, Anna Elgart, Dorit Mimrod, Sivan Weiss, Ofer Spiegelstein
Publikováno v:
Clinical Pharmacology in Drug Development. 9:1015-1024
Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod. To determine the drug-drug interact
Autor:
Ofer Spiegelstein, Paul P. Yeung, Michele Rasamoelisolo, Esther Yoon, Ernesto Aycardi, Pippa S. Loupe, Nicola Faulhaber, Orit Cohen-Barak, Sivan Weiss, Mohit D Gandhi
Publikováno v:
Cephalalgia. 38:1960-1971
Objectives The primary and secondary objectives of this phase 1 study were to evaluate the pharmacokinetic profile, safety, and immunogenicity of fremanezumab subcutaneous (sc) doses tested in phase 2 and 3 trials (225 mg, 675 mg and 900 mg) followin
Autor:
Leif Bjermer, Sivan Weiss, Catherine Lemière, Jorge Maspero, Matthew Germinaro, James Zangrilli
Publikováno v:
Chest. 150(4):789-798
Background This phase 3 study further characterizes the efficacy and safety of reslizumab (a humanized anti-IL-5 monoclonal antibody) in patients aged 12 to 75 years with asthma inadequately controlled by at least a medium-dose inhaled corticosteroid
Autor:
Megan J, Shram, Orit, Cohen-Barak, Bijan, Chakraborty, Merav, Bassan, Kerri A, Schoedel, Hussein, Hallak, Eli, Eyal, Sivan, Weiss, Yossi, Gilgun-Serki, Yossi, Gilgun, Edward M, Sellers, Janice, Faulknor, Ofer, Spiegelstein
Publikováno v:
Journal of Clinical Psychopharmacology. 35:396-405
UNLABELLED Cocaine dependence presents a major public health issue, and to date, no pharmacotherapies are approved for its treatment. TV-1380 is a novel recombinant albumin-fused mutated butyrylcholinesterase (Albu-BChE) that has increased catalytic
Publikováno v:
ERJ Open Research
ERJ OPEN RESEARCH
ERJ Open Research, Vol 3, Iss 3 (2017)
ERJ OPEN RESEARCH
ERJ Open Research, Vol 3, Iss 3 (2017)
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies. This s
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Publikováno v:
PULMONARY PHARMACOLOGY & THERAPEUTICS
INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma. METHODS: D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de6767975175161cfcd4fbae96007e8
https://biblio.ugent.be/publication/8515332/file/8515353
https://biblio.ugent.be/publication/8515332/file/8515353
Publikováno v:
5.1 Airway Pharmacology and Treatment.
Background: RES reduced exacerbation frequency and improved lung function and asthma control in pts with inadequately controlled asthma and elevated blood EOS in two placebo (PBO)-controlled, phase 3 studies (Castro et al. Lancet Resp Med 2015). Aims
Autor:
Janice Canvin, Saku Jp Torvinen, Robert C. Noble, Sivan Weiss, Marla Curran, James Zangrilli, Xichun Sun, Ratko Djukanovic
Publikováno v:
1.1 Clinical Problems.
Background: A tool to aid early identification of reslizumab (RES) responders (R) at week (wk)16 could guide continued therapy for patients (pts) with inadequately controlled severe eosinophilic asthma (SEA) Aims: To derive an algorithm using changes
Publikováno v:
Journal of the Neurological Sciences. 286:92-98
In a large multicenter randomized, and double blind placebo controlled trial of glatiramer acetate (GA) in primary progressive multiple sclerosis (PPMS), an originally unplanned post hoc analysis suggested that males assigned to GA therapy experience